BEGIN:VCALENDAR
VERSION:2.0
PRODID:icalendar-ruby
CALSCALE:GREGORIAN
BEGIN:VTIMEZONE
TZID:America/Chicago
BEGIN:DAYLIGHT
DTSTART:20220313T030000
TZOFFSETFROM:-0600
TZOFFSETTO:-0500
RRULE:FREQ=YEARLY;BYDAY=2SU;BYMONTH=3
TZNAME:CDT
END:DAYLIGHT
BEGIN:STANDARD
DTSTART:20221106T010000
TZOFFSETFROM:-0500
TZOFFSETTO:-0600
RRULE:FREQ=YEARLY;BYDAY=1SU;BYMONTH=11
TZNAME:CST
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTAMP;TZID=America/Chicago:20261015T231255
UID:168339@calendar.wisc.edu
DTSTART;TZID=America/Chicago:20221103T153000
DTEND;TZID=America/Chicago:20221103T164500
DESCRIPTION:Subgroup Mortality Results for Remdesivir in COVID-19: Real or 
 the Play of Chance?. This lecture is for a general clinical trials and pub
 lic health audience. \n\nDr. Proschan's talk describes the Adaptive COVID-
 19 Treatment Trial (ACTT-1)\, the first randomized controlled trial showin
 g a beneficial effect of a treatment for COVID-19. Experimental subjects w
 ho received remdesivir plus standard care fared better than controls\, and
  supplemental oxygen seems to have a striking effect on patient recovery. 
 Is this real? If real\, does it reflect overall mortality or a subgroup ef
 fect?\n\nCONTACT: ypark56@wisc.edu\n\nURL: https://biostat.wisc.edu/events
 /demets-lecture-series/\n\nONLINE: https://uwmadison.zoom.us/j/98834206107
LOCATION:1335 Health Sciences Learning Center  (Also offered online)
SUMMARY:DeMets Lecture Series with Dr. Michael Proschan\, NIAID
URL;VALUE=URI:https://biostat.wisc.edu/events/demets-lecture-series/
END:VEVENT
END:VCALENDAR